弥散性血管内凝血

Taylor FB Jr, Toh CH, Hoots WK, et al; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society of Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327-1330.

• 全文
• 摘要

Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286:1869-1878.

• 摘要

Abraham E, Reinhart K, Demeyer I, et al. Efficacy and safety of Tifacogin (recombinant tissue pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238-247.

• 摘要

Franchini M, Manzato F, Salvagno GL, et al. Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review. Blood Coagul Fibrinolysis. 2007;18:589-593.

• 摘要

Moscardo F, Perez F, de la Rubia J, et al. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Haematol. 2001;114:174-176.

• 摘要

Bajaj MS, Bajaj SP. Tissue pathway inhibitor: potential therapeutic applications. Thromb Haemost. 1997;78:471-477.

• 摘要

1.  Levi M, De Jonge E, van der Poll T. New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann Med. 2004;36:41-49.

• 摘要

2.  Franchini M, Lippi G, Manzato F. Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation. Thromb J. 2006;4:4.

• 全文
• 摘要

3.  Taylor FB Jr, Toh CH, Hoots WK, et al; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society of Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327-1330.

• 全文
• 摘要

4.  Avvisati G, ten Cate JW, Buller HR, et al. Tranexamic acid for control of hemorrhage in acute promyelocytic leukemia. Lancet. 1989;2:122-124.

• 摘要

5.  Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286:1869-1878.

• 摘要

6.  Abraham E, Reinhart K, Demeyer I, et al. Efficacy and safety of Tifacogin (recombinant tissue pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238-247.

• 摘要

7.  Franchini M, Manzato F, Salvagno GL, et al. Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review. Blood Coagul Fibrinolysis. 2007;18:589-593.

• 摘要

8.  Moscardo F, Perez F, de la Rubia J, et al. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Haematol. 2001;114:174-176.

• 摘要

9.  Munoz MC, Montes R, Hermida J, et al. Effect of the administration of recombinant hirudin and or tissue-plasminogen activator (T-PA) on endotoxin-induced disseminated intravascular coagulation model in rabbits. Br J Haematol. 1999;105:117-121.

• 摘要

10.  Bajaj MS, Bajaj SP. Tissue pathway inhibitor: potential therapeutic applications. Thromb Haemost. 1997;78:471-477.

• 摘要

11.  Abraham E. Tissue factor inhibition and clinical trials results of tissue pathway inhibitor in sepsis. Crit Care Med. 2000;28:S31-S33.

• 摘要

12.  Moons AH, Peters RJ, Cate H, et al. Recombinant nematode anticoagulant protein c2, a noval inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees. Thromb Haemost. 2002;88:627-631.

• 摘要

13.  Pajkrt D, van der Poll T, Levi M, et al. Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. Blood. 1997;89:2701-2705.

• 摘要

14.  Vincent JL, Ramesh MK, Ernest D, et al. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med. 2013;41:2069-2079.

• 摘要